Germline Structural Variant Identification and Functional Determination in Childhood Cancer

儿童癌症的种系结构变异鉴定和功能测定

• 批准号: 10314873
• 负责人: OWEN Robert HIRSCHI
• 金额: $ 4.36万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10314873
• 关键词: Adult; Algorithms; Alveolar Rhabdomyosarcoma; Artificial Intelligence; Bioinformatics; Biological Assay; CRISPR/Cas technology; Cancer Biology; Cancer Patient; Cell Proliferation; Characteristics; Child; Childhood; Childhood Ependymoma; Cohort Studies; DNA biosynthesis; Data; Databases; Detection; Dinoprostone; Embryonal Rhabdomyosarcoma; Engineering; Enhancers; Enrollment; Ependymal Cell; Ependymoma; Event; Exons; Fellowship; Funding; Genetic; Gold; Graph; Hereditary Nonpolyposis Colorectal Neoplasms; Inherited; Interleukin-6; Link; MSH2 gene; Malignant Childhood Neoplasm; Malignant Neoplasms; Malignant neoplasm of pancreas; Methodology; Methods; Neuroglia; Oxidoreductase; Parents; Pathogenicity; Patients; Philadelphia Chromosome; Play; Posterior Fossa; Predisposition; Promoter Regions; Prostaglandins; Proteins; Radial; Recurrence; Reporting; Rhabdomyosarcoma; Role; Running; STAT3 gene; Sensitivity and Specificity; Signal Transduction; Solid; Stat3 Signaling Pathway; Structure; Syndrome; Techniques; Testing; Training; Training Activity; Tumor Promoters; United States National Institutes of Health; Up-Regulation; Validation; Variant; Visualization; analysis pipeline; base; bioinformatics tool; cancer care; cancer predisposition; cancer prevention; cancer risk; cell type; clinical care; cohort; ethnic diversity; exome; exome sequencing; functional gain; genome sequencing; genomic data; improved; leukemia; malignant breast neoplasm; malignant stomach neoplasm; nerve stem cell; novel; pediatric patients; proband; promoter; racial diversity; stem cells; t(9; 22)(q34; q11); tool; transcriptome; transcriptome sequencing; tumor; variant detection; whole genome

Abstract A few germline pathogenic structural variants (SV) have been identified in cancer predisposition syndromes, e.g., MSH2 inversion in Lynch syndrome. The advent of short-read whole-genome sequencing (WGS) has facilitated the detection of SVs. However, a pitfall of this sequencing methodology is the inability to capture all SVs, given the reads do not map well to low complexity regions, and current algorithms used to identify SVs from short-read data have very low sensitivity and very high false-positive rates. One of the objectives of this fellowship is to optimize and implement an SV calling pipeline that utilizes multiple algorithms to increase the sensitivity and specificity of variant identification from germline short-read WGS trios. This pipeline is currently being developed and tested on pediatric cancer patients enrolled in the NIH-funded Baylor Advancing Sequencing into Childhood Cancer Care (BASIC3) exome study, which consists of ethnically and racially diverse pediatric patients with solid (CNS and non-CNS) tumors. This BASIC3 subset includes 63 proband/parent trios who have subsequently undergone germline short-read WGS. Five SV callers are run and then filtered using either a percent reciprocal overlap filter or a proposed Artificial Intelligence-based proximity graph filter to identify de novo and inherited SVs. This cohort has recently been selected for a long-read sequencing pilot, data which serves as the gold standard for SV detection. Comparison of short-read WGS generated SV calls with the long- read data will help determine the sensitivity and specificity of variant calls and further improve the short read pipeline (Aim 1A). Once optimized this short-read WGS SV pipeline will be applied to the Kids First Genetics of Embryonal and Alveolar Rhabdomyosarcoma cohort (n=900), as an independent assessment of the method and also to identify recurrent germline SVs in this cancer which has not yet been well characterized (Aim 1B). The second training and scientific objective is to explore the functional effect of a novel de novo SV identified through the initial analysis. A de novo germline duplication of the Prostaglandin Reductase 2 (PTGR2) enhancer and promoter region was found in a pediatric Posterior Fossa subtype A (PF–A) ependymoma patient. Transcriptome data from the patient’s tumor revealed increased PTGR2 expression. The PTGR2 protein converts 15-keto- prostaglandin E2 to 15-keto-13,14-dihydro-PGE2. Studies in adult malignancies suggest that increased 15-keto- 13,14-dihydro-PGE2 is associated with cancer risk potentially through the STAT3 signaling pathway. Increased STAT3 signaling is reported as a distinct feature of PF-A ependymoma. The identified partial duplication of PTGR2 will be engineered into ependymoma progenitor cells, to functionally assess the effects on STAT3 signaling, cell proliferation, and DNA synthesis. In parallel, further analysis of PTGR2 expression and structural variants will be analyzed in pediatric ependymoma cohorts (Aim 2). Completion of this experimental plan and described training activities under Drs. Plon and Milosavljevic will provide Owen Hirschi highly interdisciplinary training in analysis of genomic data, structural variation, and the downstream effects on pediatric cancer biology.

摘要